A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test
2026年6月30日 更新者:bioLytical Laboratories
A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test by Trained Personnel at Near-Patient or Point-of-Care Settings
The objective of this study is to evaluate the performance, usability, and contrived result interpretation of iStatis Gonorrhea Antigen Test (iStatis Gonorrhea Test) in the intended near-patient or point-of-care setting by trained personnel.
調査の概要
詳細な説明
The study is designed to evaluate iStatis Gonorrhea Test performance when used by trained personnel as follows:
- A method comparison will be performed to determine the diagnostic sensitivity and specificity of the iStatis Gonorrhea Test compared to a reference test that is an approved, current on-market Gonorrhea/Chlamydia combo assay, Cobas CT/NG.
- To evaluate the usability of iStatis Gonorrhea Test by means of assessing user experience via a questionnaire in combination with the success in performing the test. A minimum of 15 intended users to participate in the usability evaluation.
- To evaluate and document whether intended users (trained personnel), a minimum of 15 intended users across a minimum of three (3) sites, can successfully interpret contrived iStatis Gonorrhea Test results that include - strong positive, weak positive, negative and a range of invalid results.
研究の種類
介入
入学 (推定)
650
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Ana Subramanian
- 電話番号:16042046784
- メール:asubramanian@biolytical.com
研究連絡先のバックアップ
- 名前:Patrick Diaz
- 電話番号:16042046784
- メール:pdiaz@biolytical.com
研究場所
-
-
Gauteng
-
Johannesburg、Gauteng、南アフリカ、2193
- 募集
- Epicentre Health Research (Johannesburg)
-
コンタクト:
- Cherie Cawood
- 電話番号:+42 082 065 2172
- メール:cheriec@epicentre.org.za
-
-
KwaZulu-Natal
-
Durban、KwaZulu-Natal、南アフリカ、3650
- 募集
- Epicentre Health Research
-
コンタクト:
- Cherie Cawood
- 電話番号:+27 31 880 2150
- メール:cheriec@epicentre.org.za
-
-
Western Cape
-
Cape Town、Western Cape、南アフリカ、7925
- 募集
- Epicentre Health Research (Cape Town)
-
コンタクト:
- Cherie Cawood
- 電話番号:+27 21 201 1658
- メール:cheriec@epicentre.org.za
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria
- Age > 16 years
- Subject (or legally authorized representative) is willing to provide written informed consent before any study procedures
- Female gender
- Subject is able and willing to provide vaginal swab specimen for study procedures (3-4 swabs)
- Subject can complete the required testing on the allocated testing day
- Subject can speak, read, and write English
- Subject's demographic information, risk factors, and symptoms are available and can be recorded on case report forms
- Subject agrees to comply with study procedures and sample collection for both the investigational device and the reference method
- Subject is willing to participate in the study site's standard-of-care Gonorrhea counselling and testing program and receive standard-of-care test results, as required and applicable
Subject is indicated for sexually transmitted infection testing for one or more of the following reasons:
- At risk of Gonorrhea, such as recent unprotected intercourse, multiple or new partners within < 60 days, known exposure to an infected partner, or prior STI history
- Having signs and/or symptoms suggestive of Gonorrhea (e.g., urethral, vaginal, rectal, or pharyngeal discharge; dysuria; pelvic or lower-abdominal pain; sore throat; or rectal discomfort)
- Undergoing routine or opportunistic STI screening, including family-planning, antenatal, or sexual-health clinic visits
- Undergoing re-testing (test-of-cure) > 7 days after completion of Gonorrhea treatment and clinically stable
- Undergoing co-testing for other STIs where Gonorrhea testing is part of a broader diagnostic panel
Exclusion Criteria
- Subject 15 years of age or younger
- Male gender
- Female currently menstruating
- Subject is unable or unwilling to provide informed consent
- Subject is medically unstable or has psychiatric condition(s) that pose a risk or prevent study compliance
- Subject is unable to provide paired samples for reference testing
- Subject requires urgent antimicrobial treatment before specimen collection
- Subject received systemic or topical antibiotics active against Gonorrhea within the previous 7 days
- Subject used topical intravaginal or rectal antiseptics within 48 hours prior to study sampling
- Previously enrolled for the same infection episode
- Anatomical or clinical contraindication to study sampling (e.g., severe cervical pathology)
- Recent urogenital procedure (e.g., cystoscopy, lavage) < 72 hours before study sampling
- Subject belongs to a protected group excluded by local ethics (e.g., incarcerated persons), unless explicitly approved by the EC/IRB
- Any condition that, in the opinion of trained personnel or study staff, would make the participant unsuitable or unsafe for enrolment, interfere with completion of assessments, consent, or questionnaires, or bias study outcomes
- Subject is participating in another interventional clinical study within 30 days that could interfere with study results
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:iStatis Gonorrhea Test Performance (Operator-collected swabs)
Operator-collected vaginal swabs will be tested on the iStatis Gonorrhea Test
|
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
|
|
実験的:iStatis Gonorrhea Test Performance (Self-collected swabs)
Self-collected vaginal swabs will be tested on the iStatis Gonorrhea Test.
Participants assigned to the self-collection arm of the study will complete the self-collection Usability Questionnaire
|
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
|
|
介入なし:Reference Test to evaluate iStatis Performance
Vaginal swabs collected for reference testing will be tested using the Cobas CT/NG reference assay to determine the gonorrhea infection status of participants.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Performance Evaluation
時間枠:3 months
|
The performance between iStatis Gonorrhea Test and the reference test result for vaginal swabs (operator-collected and self-collected) will be calculated for all sites combined.
Diagnostic sensitivity and specificity values and 95% CIs will be calculated for all subjects combined.
The percentage of invalids (tests that fail to produce a control dot with accurate use) will be identified and reported.
|
3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
iStatis Gonorrhea Test usability evaluation
時間枠:3 months
|
Overall test usability and self collection usability will be determined via a questionnaire completed by trained personnel who used the device during testing and study participants that performed sample self-collection respectively.
The usability questionnaire will use a scale of one (1) to 5 (1 - very difficult/very unlikely to 5 - very easy/very likely), with a rating of 3 being satisfactory.
|
3 months
|
|
iStatis Gonorrhea Test contrived result interpretation evaluation
時間枠:3 months
|
Trained operators will evaluate a panel of contrived (mock) iStatis devices.
These devices are designed to represent a comprehensive range of test outcomes, including strong positives, weak positives, negatives and invalid results.
Operators will interpret the results of the mock devices and record their interpretations which will be compared to the correct interpretation of the device.
|
3 months
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
協力者
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2025年11月26日
一次修了 (推定)
2026年9月1日
研究の完了 (推定)
2027年1月1日
試験登録日
最初に提出
2026年4月21日
QC基準を満たした最初の提出物
2026年4月29日
最初の投稿 (実際)
2026年5月6日
学習記録の更新
投稿された最後の更新 (実際)
2026年7月2日
QC基準を満たした最後の更新が送信されました
2026年6月30日
最終確認日
2026年4月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- CLS-009A
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。